XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:        
Total revenue $ 18,000 $ 25,000
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] IBO:BiotechRetailSalesMember   IBO:BiotechRetailSalesMember  
Costs and expenses:        
Cost of revenue $ 1,000 $ 2,000
Sales, general and administrative compensation (inclusive of stock-based compensation) 261,000 132,000 755,000 424,000
Sales and marketing 2,000 461,000 22,000 487,000
Professional Fees 234,000 122,000 868,000 313,000
Research and development 52,000 82,000 230,000 386,000
Depreciation and Amortization 288,000 281,000 859,000 840,000
Rent and utilities 19,000 4,000 56,000 14,000
Other operating expenses 109,000 45,000 345,000 58,000
Total costs and expenses 966,000 1,127,000 3,137,000 2,522,000
Operating loss (948,000) (1,127,000) (3,112,000) (2,522,000)
Other income (expense):        
Interest income 3,000 3,000 10,000 10,000
Change in fair value of note payable, related party (268,000) 5,670,000 (13,210,000) 5,670,000
Interest expense (262,000) (305,000) (793,000) (795,000)
(Loss) income from operations before income taxes (1,475,000) 4,241,000 (17,105,000) 2,363,000
Income tax benefit
Net (loss) income (1,475,000) 4,241,000 (17,105,000) 2,363,000
Loss from operations attributed to noncontrolling interest 5,000 6,000 22,000 37,000
Net (loss) income attributable to common stockholders $ (1,470,000) $ 4,247,000 $ (17,083,000) $ 2,400,000
(Loss) earnings per common share:        
Basic $ (0.12) $ 0.37 $ (1.41) $ 0.23
Diluted $ (0.12) $ 0.06 $ (1.41) $ 0.03
Shares used in computing (loss) earnings per common share:        
Basic 12,185,412 11,503,955 12,144,972 10,506,394
Diluted 12,185,412 71,999,996 12,144,972 71,002,435